Drug Profile
Tuberculosis vaccine - Genesis Research and Development
Alternative Names: MED-1Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Genesis Research and Development
- Class Antituberculars; Recombinant fusion proteins; Tuberculosis vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Tuberculosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Tuberculosis in New Zealand (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Tuberculosis in Philippines (Parenteral)
- 08 Nov 2010 Tuberculosis vaccine - Genesis Research and Development is available for licensing as of 14 Mar 2008. http://www.genesis.co.nz/